One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients.

Nico C B de JagerLaura H Bukkems Jessica M HeijdraCarolien H C A M HazendonkKarin FijnvandraatKarina MeijerJeroen C J EikenboomBritta A P Laros-van GorkomFrank W G LeebeekMarjon H CnossenRon A A Mathôtnull null

Published in: Journal of thrombosis and haemostasis : JTH (2019)

This population PK model derived from real world data adequately describes FVIII levels following perioperative administration of the FVIII/VWF plasma-derived concentrate (Haemate® P/Humate P® ) and will help to facilitate future dosing in VWD patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
cardiac surgery
patients undergoing
smoking cessation